Inhibrx is a startup based in the United States, most recent round Series-c-plus, 2 tracked investors.
Inhibrx is a company headquartered in the United States. Its most recent tracked round is Series-c-plus. Brouky records 2 investors associated with the company.
Inhibrx is a clinical-stage biopharmaceutical company that designs and develops biologic therapeutics using a proprietary single-domain antibody and protein-engineering platform. The company advances targeted immunotherapy and other biologic candidates through clinical development for serious and life‑threatening conditions.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.